Prolotherapy predates platelet-rich plasma by decades, and if you've been quoted a price for PRP, you may also have been offered prolotherapy as a cheaper alternative — or as a series of "primer" injections before it. The two treatments share a premise: injure the tissue slightly, on purpose, and the body's repair response does the rest. They differ enormously in what's injected, what it costs, and how much research exists.

This guide is information, not medical advice. Decisions about your joints belong to you and a clinician who has examined you.

What prolotherapy actually is

Prolotherapy — short for "proliferation therapy" — is the injection of an irritant solution into and around ligaments, tendons, and joint capsules that are thought to be a source of chronic pain. The most common solution in modern American practice is hypertonic dextrose (sugar water), typically diluted to somewhere between 10% and 25% and mixed with a local anesthetic such as lidocaine.

Older formulas used more aggressive agents: phenol-glycerin-glucose ("P2G"), sodium morrhuate (a cod-liver-oil derivative), and various sclerosants. Some clinicians still use these. Dextrose has largely won out because it is cheap, familiar, and appears to be well tolerated.

The technique matters as much as the solution. A prolotherapy session usually involves many small injections — sometimes a dozen or more — placed at tendon and ligament attachment points identified by palpation or ultrasound, rather than one large injection into a joint space. A typical course is three to six sessions spaced two to six weeks apart.

The proposed mechanism, and why it's contested

The classical explanation is that a hypertonic solution causes a small, controlled inflammatory injury; inflammation recruits growth factors and fibroblasts; fibroblasts lay down collagen; the ligament tightens and the joint stabilizes. That story is appealing and largely inferred. Animal and small human studies have shown some changes in tissue after dextrose injection, but the evidence that clinical pain relief comes from new collagen is weak.

An alternative explanation that has gained ground is neurogenic: dextrose may act on sensory nerve endings and reduce the signaling that maintains chronic pain, which would explain why some patients report relief within days — far too fast for tissue remodeling. Both mechanisms may contribute. Neither is settled.

This is worth knowing because the mechanism is often sold to patients as established fact. It isn't.

What it's used for

In the joint, sports, and spine world, prolotherapy is most often offered for:

  • Knee osteoarthritis, usually as a combination of intra-articular and peri-articular injections
  • Chronic low back pain, particularly pain attributed to sacroiliac joints or lumbar ligaments
  • Tendinopathy — lateral epicondylitis (tennis elbow), Achilles, gluteal, patellar
  • Plantar fasciitis
  • Sacroiliac and coccygeal pain
  • Shoulder pain and rotator cuff tendinopathy
  • Osgood-Schlatter disease in adolescent athletes
  • Temporomandibular joint pain and, in some practices, joint hypermobility

That is a long list, and the length itself is a caution. The breadth of indications reflects how prolotherapy is practiced, not the breadth of the trial evidence supporting it.

What the evidence shows

Knee osteoarthritis is where prolotherapy has its best data. Several randomized controlled trials of dextrose injections have reported meaningful improvements in pain and function versus saline injection or exercise alone, with benefits persisting at a year in some studies. The trials are small — often 30 to 90 participants per arm — conducted at single sites, and hard to blind convincingly, since the injections themselves sting. A patient who feels a strong sting knows they got the active solution. Meta-analyses pooling these studies have generally found a positive effect on pain scores while flagging high heterogeneity and moderate-to-high risk of bias (search the trial literature on PubMed).

Chronic low back pain is where the evidence is genuinely mixed. A Cochrane review of prolotherapy injections for chronic low-back pain (Dagenais and colleagues, 2007) concluded there was no consistent evidence that prolotherapy injections alone were more effective than control injections, though co-interventions such as spinal manipulation and exercise appeared to matter (Cochrane and related reviews indexed on PubMed). That review is old, and the field has not produced a large, well-powered replacement trial since. "No good recent evidence" is not the same as "proven useless," but it is not a green light either.

Tendinopathy evidence is thinner still: a handful of small trials in tennis elbow, Achilles, and plantar fascia, some positive, none large enough to be definitive.

Specialty guidelines have not embraced it. The 2019 American College of Rheumatology / Arthritis Foundation guideline for hand, hip, and knee osteoarthritis recommends against prolotherapy, citing insufficient evidence and a lack of standardization in how it is performed; the same guideline recommends against platelet-rich plasma for knee and hip OA more strongly, on the grounds that PRP preparations vary so wildly between clinics that the trials cannot be pooled (guideline listing on PubMed). The AAOS clinical practice guideline for knee osteoarthritis similarly does not endorse injectable regenerative therapies as standard care.

How this compares with PRP

Honest summary: PRP has more studies, prolotherapy has arguably cleaner ones.

PRP for knee osteoarthritis has been studied in dozens of randomized trials and multiple meta-analyses. Prolotherapy has perhaps a dozen decent randomized trials across all indications combined. On volume, PRP wins.

But PRP's literature has a specific problem: "PRP" is not one thing. Platelet concentration, leukocyte content, activation method, volume, and injection frequency differ between studies and between clinics, so a positive trial of one preparation says little about the syringe you'll actually receive. Prolotherapy has its own variability problem — injection sites and dextrose concentrations differ — but 20% dextrose is 20% dextrose everywhere.

A few head-to-head trials comparing dextrose prolotherapy with PRP in knee OA and tendinopathy exist. They are small, and results have been broadly comparable rather than showing one clearly superior. That is not the same as showing both work; two treatments can be equivalent and both modest.

The practical differences that will show up in your life:

  • Cost. Prolotherapy commonly runs in the low hundreds of dollars per session, with a course of three to six sessions. PRP is typically several hundred to a few thousand dollars per injection. Neither is usually covered. Medicare has a longstanding national coverage determination excluding prolotherapy on the grounds that its effectiveness has not been established by controlled studies, and most commercial plans follow suit.
  • Number of visits. Prolotherapy courses are usually longer.
  • Discomfort. Prolotherapy involves more needle passes and a well-documented post-injection flare of pain and stiffness for a few days.

Regulation: read this part carefully

Dextrose injection is an FDA-approved drug — but it is approved as a source of calories and fluid, not as a treatment for arthritis or tendon pain. Injecting it into a ligament to relieve pain is off-label use of an approved drug. Off-label prescribing is legal and common in medicine, and it is not a scandal, but it does mean the FDA has never reviewed evidence that this use works or is safe (FDA: understanding unapproved use of approved drugs).

PRP sits in a different regulatory box — generally treated as the practice of medicine using cleared preparation devices, with no FDA approval for orthopedic indications either. The FDA has repeatedly cautioned patients that many marketed regenerative treatments are neither approved nor proven (FDA patient information on regenerative medicine therapies).

If a clinic tells you prolotherapy is "FDA-approved because dextrose is FDA-approved," that is a sleight of hand worth naming out loud.

Safety

Dextrose prolotherapy appears to have a favorable safety profile in published trials, with adverse events mostly limited to post-injection pain, swelling, stiffness, and bruising lasting a few days. Serious complications are rare but not impossible: any injection carries infection risk, and injections near the spine carry the additional risks of nerve injury and, very rarely, dural puncture. The historic case reports of severe neurological injury involved sclerosant solutions injected near the spinal canal, not intra-articular dextrose — which is one reason to ask specifically what solution a clinician uses and where they intend to put it.

Prolotherapy is generally avoided during acute infection, in people on anticoagulants without adjustment, and in patients with poorly controlled diabetes when large dextrose volumes are planned.

Questions worth asking before you pay

  • What exact solution and concentration, and is any sclerosant involved?
  • How many sessions before we decide it isn't working — and what is the stopping rule?
  • Is ultrasound guidance used, and for which targets?
  • What does the total course cost, all-in, including follow-ups?
  • What non-injection care am I doing alongside this? In back pain trials, the exercise and manual therapy given to both groups may have done much of the work.

Bottom line

Prolotherapy is a plausible, inexpensive, low-tech option with a small, mostly encouraging evidence base in knee osteoarthritis, weak evidence in chronic low back pain, and thin evidence elsewhere. It is not FDA-approved for any of these uses, no major specialty guideline recommends it, and insurers do not pay for it. If you are choosing between prolotherapy and PRP for a knee, the honest framing is that neither is established, prolotherapy is far cheaper, and PRP has more studies of lower interpretability. Anyone who presents either as a settled cure is telling you something the literature does not support.